Metabolic associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide, affecting nearly a quarter of the global population. The rising incidence of obesity, diabetes, and metabolic syndrome has driven this surge, making MASLD a leading cause of advanced liver disease, including cirrhosis and hepatocellular carcinoma. As these conditions progress, MASLD is expected to surpass alcohol and viral hepatitis as the leading indication for liver transplantation ...